This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654SiegelRLMillerKDFuchsHEJemalACancer statistics, 2021CA Cancer J Clin20217173310.3322/caac.21654Open DOISearch in Google Scholar
Eurostat. Cancer statistics - statistics explained. [cited 2021 Nov 18]. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_statistics#Deaths_from_cancerEurostatCancer statistics - statistics explained. [cited 2021 Nov 18]Available athttps://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_statistics#Deaths_from_cancerSearch in Google Scholar
Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol 2021; 55: 42-9. doi: 10.2478/raon-2021-0003ZadnikVZagarTLokarKTomsicSKonjevicADZakotnikBTrends in population-based cancer survival in SloveniaRadiol Oncol20215542910.2478/raon-2021-0003Open DOISearch in Google Scholar
Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4: 218-27. doi: 10.3121/cmr.4.3.218CrossDBurmesterJKGene therapy for cancer treatment: past, present and futureClin Med Res200642182710.3121/cmr.4.3.218Open DOISearch in Google Scholar
Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, et al Gene therapy leaves a vicious cycle. Front Oncol 2019; 9: 1-25. doi: 10.3389/fonc.2019.00297GoswamiRSubramanianGSilayevaLNewkirkIDoctorDChawlaKet alGene therapy leaves a vicious cycleFront Oncol2019912510.3389/fonc.2019.00297Open DOISearch in Google Scholar
Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29: 121-8. doi: 10.1038/nbt.1769SheridanCGene therapy finds its nicheNat Biotechnol201129121810.1038/nbt.1769Open DOISearch in Google Scholar
Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 2015; 17: 63-89. doi: 10.1146/annurev-bioeng-071813-104938KottermanMAChalbergTWSchafferDVViral vectors for gene therapy: translational and clinical outlookAnnu Rev Biomed Eng201517638910.1146/annurev-bioeng-071813-104938Open DOISearch in Google Scholar
Daley J. Gene therapy arrives. Nature 2019; 576: S12-3. doi: 10.1038/d41586-019-03716-9DaleyJGene therapy arrivesNature2019576S12310.1038/d41586-019-03716-9Open DOISearch in Google Scholar
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384: 2187-201. doi: 10.1056/NEJMoa2101544SadoffJGrayGVandeboschACárdenasVShukarevGGrinsztejnBet alSafety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19N Engl J Med2021384218720110.1056/NEJMoa2101544Open DOISearch in Google Scholar
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99-111. doi: 10.1016/S0140-6736(20)32661-1VoyseyMClemensSACMadhiSAWeckxLYFolegattiPMAleyPKet alSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKLancet20213979911110.1016/S0140-6736(20)32661-1Open DOISearch in Google Scholar
Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med 2018; 20: 1-16. doi: 10.1002/jgm.3015GinnSLAmayaAKAlexanderIEEdelsteinMAbediMRGene therapy clinical trials worldwide to 2017: an updateJ Gene Med20182011610.1002/jgm.301529575374Open DOISearch in Google Scholar
Dock G. The influence of compliting disease upon leukaemia. Am J Med Sci 1904; 127: 563-92.DockGThe influence of compliting disease upon leukaemiaAm J Med Sci19041275639210.1097/00000441-190412740-00001Search in Google Scholar
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-9. doi: 10.1038/sj.mt.6300108KellyERussellSJHistory of oncolytic viruses: genesis to genetic engineeringMol Ther200715651910.1038/sj.mt.630010817299401Open DOISearch in Google Scholar
Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2014; 12: 23-34. doi: 10.1038/nrmicro3140MiestTSCattaneoRNew viruses for cancer therapy: meeting clinical needsNat Rev Microbiol201412233410.1038/nrmicro3140400250324292552Open DOISearch in Google Scholar
Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 2021; 6: 53. doi: 10.1038/s41392-021-00487-6BulchaJTWangYMaHTaiPWLGaoGViral vector platforms within the gene therapy landscapeSignal Transduct Target Ther202165310.1038/s41392-021-00487-6786867633558455Open DOISearch in Google Scholar
Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer 2021; 21: 360-78. doi: 10.1038/s41568-021-00346-0SaxenaMvander Burg SHMeliefCJMBhardwajNTherapeutic cancer vaccinesNat Rev Cancer2021213607810.1038/s41568-021-00346-033907315Open DOISearch in Google Scholar
Wan PKT, Ryan AJ, Seymour LW. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther 2021; 29: 1668-82. doi: 10.1016/j.ymthe.2021.04.015WanPKTRyanAJSeymourLWBeyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virusMol Ther20212916688210.1016/j.ymthe.2021.04.015811663433845199Open DOISearch in Google Scholar
Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65: 333-47. doi: 10.1146/annurev-med-060512-150254BarrettDMSinghNPorterDLGruppSAJuneCHChimeric antigen receptor therapy for cancerAnnu Rev Med2014653334710.1146/annurev-med-060512-150254412007724274181Open DOISearch in Google Scholar
Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 2021; 18: 85-100. doi: 10.1038/s41571-020-0426-7MyersJAMillerJSExploring the NK cell platform for cancer immunotherapyNat Rev Clin Oncol2021188510010.1038/s41571-020-0426-7831698132934330Open DOISearch in Google Scholar
Shaw AR, Suzuki M. Immunology of adenoviral vectors in cancer therapy. Mol Ther Methods Clin Dev 2019; 15: 418-29. doi: 10.1016/j. omtm.2019.11.001ShawARSuzukiMImmunology of adenoviral vectors in cancer therapyMol Ther Methods Clin Dev2019154182910.1016/j.omtm.2019.11.001690912931890734Open DOISearch in Google Scholar
McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15: 1022-33. doi: 10.1089/hum.2004.15.1022McConnellMJImperialeMJBiology of adenovirus and its use as a vector for gene therapyHum Gene Ther20041510223310.1089/hum.2004.15.102215610603Open DOISearch in Google Scholar
Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 2013; 13: 421-33. doi: 10.2174/1566 523213666131125095046WoldWSMTothKAdenovirus vectors for gene therapy, vaccination and cancer gene therapyCurr Gene Ther2013134213310.2174/1566523213666131125095046Open DOISearch in Google Scholar
Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-27. doi: 10.1089/hum.2005.16.1016PengZCurrent status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancersHum Gene Ther20051610162710.1089/hum.2005.16.1016Open DOISearch in Google Scholar
Wang D, Wang K, Cai Y. An overview of development in gene therapeutics in China. Gene Ther 2020; 27: 338-48. doi: 10.1038/s41434-020-0163-7WangDWangKCaiYAn overview of development in gene therapeutics in ChinaGene Ther2020273384810.1038/s41434-020-0163-7Open DOISearch in Google Scholar
Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, et al Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 823-33. doi: 10.1016/S1470-2045(13)70274-2WestphalMYlä-HerttualaSMartinJWarnkePMeneiPEcklandDet alAdenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trialLancet Oncol2013148233310.1016/S1470-2045(13)70274-2Open DOISearch in Google Scholar
European Medicines Agency. Ark Therapeutics Ltd withdraws its marketing authorisation application for Cerepro (sitimagene ceradenovec). [cited 2021 Dec 21]. Available at: https://www.ema.europa.eu/en/news/ark-therapeutics-ltd-withdraws-its-marketing-authorisation-application-cerepro-sitimageneEuropean Medicines AgencyArk Therapeutics Ltd withdraws its marketing authorisation application for Cerepro (sitimagene ceradenovec). [cited 2021 Dec 21]Available athttps://www.ema.europa.eu/en/news/ark-therapeutics-ltd-withdraws-its-marketing-authorisation-application-cerepro-sitimageneSearch in Google Scholar
Kulkarni GS. Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? Lancet Oncol 2021; 22: 8-9. doi: 10.1016/S1470-2045(20)30586-6KulkarniGSNadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?Lancet Oncol2021228910.1016/S1470-2045(20)30586-6Open DOISearch in Google Scholar
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021; 22: 107-17. doi: 10.1016/S1470-2045(20)30540-4BoorjianSAAlemozaffarMKonetyBRShoreNDGomellaLGKamatAMet alIntravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialLancet Oncol2021221071710.1016/S1470-2045(20)30540-4Open DOISearch in Google Scholar
Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7: e40385. doi: 10.1371/journal.pone.0040385DicksMDSpencerAJEdwardsNJWadellGBojangKGilbertSCet alA novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicityPLoS One20127e4038510.1371/journal.pone.0040385Open DOISearch in Google Scholar
Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 2021; 20: 832-41. doi: 10.1016/S1474-4422(21)00251-9MercuriEMuntoniFBaranelloGMassonRBoespflug-TanguyOBrunoCet alOnasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialLancet Neurol2021208324110.1016/S1474-4422(21)00251-9Open DOISearch in Google Scholar
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, et al. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. J Immunother Cancer 2020; 8: 1-13. doi: 10.1136/jitc-2020-000928CappucciniFBryantRPollockECarterLVerrillCHollidgeJet alSafety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialJ Immunother Cancer2020811310.1136/jitc-2020-000928731977532591433Open DOISearch in Google Scholar
Sato-Dahlman M, LaRocca CJ, Yanagiba C, Yamamoto M. Adenovirus and immunotherapy: advancing cancer treatment by combination. Cancers 2020; 12: 1295. doi: 10.3390/cancers12051295Sato-DahlmanMLaRoccaCJYanagibaCYamamotoMAdenovirus and immunotherapy: advancing cancer treatment by combinationCancers202012129510.3390/cancers12051295728165632455560Open DOISearch in Google Scholar
Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis 2017; 4: 43-63. doi: 10.1016/j.gendis.2017.04.001LeeCSBishopESZhangRYuXFarinaEMYanSet alAdenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicineGenes Dis20174436310.1016/j.gendis.2017.04.001Open DOISearch in Google Scholar
Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-32. doi: 10.1128/JVI.72.3.2224-2232.1998XiaoXLiJSamulskiRJProduction of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirusJ Virol19987222243210.1128/JVI.72.3.2224-2232.1998Open DOISearch in Google Scholar
Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 2014; 1: 427-51. doi: 10.1146/annurev-virology-031413-085355SamulskiRJMuzyczkaNAAV-mediated gene therapy for research and therapeutic purposesAnnu Rev Virol201414275110.1146/annurev-virology-031413-085355Open DOISearch in Google Scholar
Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 2016; 21: 75-80. doi: 10.1016/j.coviro.2016.08.003SrivastavaAIn vivo tissue-tropism of adeno-associated viral vectorsCurr Opin Virol201621758010.1016/j.coviro.2016.08.003Open DOISearch in Google Scholar
Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 2021; 20: 832-41. doi: 10.1016/S1474-4422(21)00251-9MercuriEMuntoniFBaranelloGMassonRBoespflug-TanguyOBrunoCet alOnasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialLancet Neurol2021208324110.1016/S1474-4422(21)00251-9Open DOISearch in Google Scholar
Challis RC, Ravindra Kumar S, Chan KY, Challis C, Beadle K, Jang MJ, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc 2019; 14: 379-414. doi: 10.1038/s41596-018-0097-3ChallisRCRavindraKumar SChanKYChallisCBeadleKJangMJet alSystemic AAV vectors for widespread and targeted gene delivery in rodentsNat Protoc20191437941410.1038/s41596-018-0097-330626963Open DOISearch in Google Scholar
Xu X, Chen W, Zhu W, Chen J, Ma B, Ding J, et al. Adeno-associated virus (AAV)-based gene therapy for glioblastoma. Cancer Cell Int 2021; 21: 1-10. doi: 10.1186/s12935-021-01776-4XuXChenWZhuWChenJMaBDingJet alAdeno-associated virus (AAV)-based gene therapy for glioblastomaCancer Cell Int20212111010.1186/s12935-021-01776-4783618433499886Open DOISearch in Google Scholar
Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release 2016; 240: 287-301. doi: 10.1016/j. jconrel.2016.01.001Santiago-OrtizJLSchafferDVAdeno-associated virus (AAV) vectors in cancer gene therapyJ Control Release201624028730110.1016/j.jconrel.2016.01.001494032926796040Open DOISearch in Google Scholar
Hacker UT, Bentler M, Kaniowska D, Morgan M, Büning H. Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectives. Cancers 2020; 12: 1-30. doi: 10.3390/cancers12071889HackerUTBentlerMKaniowskaDMorganMBüningHTowards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectivesCancers20201213010.3390/cancers12071889740917432674264Open DOISearch in Google Scholar
Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 2013; 21: 109-18. doi: 10.1038/mt.2012.186MünchRCJanickiHVölkerIRasbachAHallekMBüningHet alDisplaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transferMol Ther2013211091810.1038/mt.2012.186353830722968478Open DOISearch in Google Scholar
Reul J, Frisch J, Engeland CE, Thalheimer FB, Hartmann J, Ungerechts G, et al Tumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectors. Front Oncol 2019; 9: 52. doi: 10.3389/fonc.2019.00052ReulJFrischJEngelandCEThalheimerFBHartmannJUngerechtsGet alTumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectorsFront Oncol201995210.3389/fonc.2019.00052638273830838171Open DOISearch in Google Scholar
Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, et al Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun 2015; 6: 6246. doi: 10.1038/ncomms7246MünchRCMuthAMuikAFriedelTSchmatzJDreierBet alOff-target-free gene delivery by affinity-purified receptor-targeted viral vectorsNat Commun20156624610.1038/ncomms724625665714Open DOISearch in Google Scholar
MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, et al Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther 2017; 25: 949-61. doi: 10.1016/j.ymthe.2017.02.005MacLeodDTAntonyJMartinAJMoserRJHekeleAWetzelKJet alIntegration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cellsMol Ther2017259496110.1016/j.ymthe.2017.02.005538362928237835Open DOISearch in Google Scholar
Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, et al Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113-7. doi: 10.1038/nature21405EyquemJMansilla-SotoJGiavridisTvan derStegen SJCHamiehMCunananKMet alTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature2017543113710.1038/nature21405555861428225754Open DOISearch in Google Scholar
Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H, et al AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J 2021; 11: 119. doi: 10.1038/s41408-021-00508-1NawazWHuangBXuSLiYZhuLYiqiaoHet alAAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemiaBlood Cancer J20211111910.1038/s41408-021-00508-1822234734162832Open DOISearch in Google Scholar
Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 2020; 181: 136-50. doi: 10.1016/j.cell.2020.03.023WangDZhangFGaoGCRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectorsCell20201811365010.1016/j.cell.2020.03.023723662132243786Open DOISearch in Google Scholar
Ibraheim R, Tai PWL, Mir A, Javeed N, Wang J, Rodríguez TC, et al. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun 2021; 12: 6267. doi: 10.1038/s41467-021-26518-yIbraheimRTaiPWLMirAJaveedNWangJRodríguezTCet alSelf-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivoNat Commun202112626710.1038/s41467-021-26518-y856086234725353Open DOISearch in Google Scholar
Zhao X, Liu L, Lang J, Cheng K, Wang Y, Li X, et al. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett 2018; 431: 171-81. doi: 10.1016/j. canlet.2018.05.042ZhaoXLiuLLangJChengKWangYLiXet alA CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatmentCancer Lett20184311718110.1016/j.canlet.2018.05.04229870774Open DOISearch in Google Scholar
Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381-90. doi: 10.1086/595830CalcedoRVandenbergheLHGaoGLinJWilsonJMWorldwide epidemiology of neutralizing antibodies to adeno-associated virusesJ Infect Dis20091993819010.1086/59583019133809Open DOISearch in Google Scholar
Venditti CP. Safety questions for AAV gene therapy. Nat Biotechnol 2021; 39: 24-6. doi: 10.1038/s41587-020-00756-9VendittiCPSafety questions for AAV gene therapyNat Biotechnol20213924610.1038/s41587-020-00756-933199877Open DOISearch in Google Scholar
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther 2020; 28: 709-22. doi: 10.1016/j. ymthe.2020.01.001ShirleyJLdeJong YPTerhorstCHerzogRWImmune responses to viral gene therapy vectorsMol Ther2020287092210.1016/j.ymthe.2020.01.001705471431968213Open DOISearch in Google Scholar
Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7. doi: 10.1126/science.272.5259.263NaldiniLBlömerUGallayPOryDMulliganRGageFHet alIn vivo gene delivery and stable transduction of nondividing cells by a lentiviral vectorScience1996272263710.1126/science.272.5259.2638602510Open DOISearch in Google Scholar
Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007; 36: 184-204. doi: 10.1007/s12033-007-0010-8CockrellASKafriTGene delivery by lentivirus vectorsMol Biotechnol20073618420410.1007/s12033-007-0010-817873406Open DOISearch in Google Scholar
Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia 2018; 32: 1529-41. doi: 10.1038/s41375-018-0106-0MiloneMCO’DohertyUClinical use of lentiviral vectorsLeukemia20183215294110.1038/s41375-018-0106-0603515429654266Open DOISearch in Google Scholar
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-71. doi: 10.1128/jvi.72.11.8463-8471.1998DullTZuffereyRKellyMMandelRJNguyenMTronoDet alA third-generation lentivirus vector with a conditional packaging systemJ Virol19987284637110.1128/jvi.72.11.8463-8471.19981102549765382Open DOISearch in Google Scholar
Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 2000; 7: 20-3. doi: 10.1038/sj.gt.3301105TronoDLentiviral vectors: turning a deadly foe into a therapeutic agentGene Ther2000720310.1038/sj.gt.330110510680011Open DOISearch in Google Scholar
Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-53. doi: 10.1038/nm1365Yáñez-MuñozRJBalagganKSMacNeilAHoweSJSchmidtMSmithAJet alEffective gene therapy with nonintegrating lentiviral vectorsNat Med2006123485310.1038/nm136516491086Open DOISearch in Google Scholar
Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, et al Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and vivo. Proc Natl Acad Sci U S A 2006; 103: 17684-9. doi: 10.1073/pnas.0606197103PhilippeSSarkisCBarkatsMMammeriHLadroueCPetitCet alLentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and vivoProc Natl Acad Sci U S A200610317684910.1073/pnas.0606197103169380717095605Open DOISearch in Google Scholar
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38. doi: 10.1126/scitranslmed.3005930BrentjensRJDavilaMLRiviereIParkJWangXCowellLGet alCD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaSci Transl Med20135177ra3810.1126/scitranslmed.3005930374255123515080Open DOISearch in Google Scholar
Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther 2018; 12: 3885-98. doi: 10.2147/DDDT.S138765VairySGarciaJLTeiraPBittencourtHCTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemiaDrug Des Devel Ther20181238859810.2147/DDDT.S138765623714330518999Open DOISearch in Google Scholar
Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 2017; 4: 92-101. doi: 10.1016/j. omtm.2016.12.006LevineBLMiskinJWonnacottKKeirCGlobal manufacturing of CAR T cell therapyMol Ther Methods Clin Dev201749210110.1016/j.omtm.2016.12.006536329128344995Open DOISearch in Google Scholar
Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther 2015; 22: 79-84. doi: 10.1038/cgt.2015.5LevineBLPerformance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cellsCancer Gene Ther201522798410.1038/cgt.2015.525675873Open DOISearch in Google Scholar
Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, et al First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res 2019; 25: 5808-17. doi: 10.1158/1078-0432.CCR-19-1025SomaiahNBlockMSKimJWShapiroGIDoKTHwuPet alFirst-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1Clin Cancer Res20192558081710.1158/1078-0432.CCR-19-102531227504Open DOISearch in Google Scholar
Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009; 32: 689-702. doi: 10.1097/CJI.0b013e3181ac6138KochenderferJNFeldmanSAZhaoYXuHBlackMAMorganRAet alConstruction and preclinical evaluation of an anti-CD19 chimeric antigen receptorJ Immunother20093268970210.1097/CJI.0b013e3181ac6138274730219561539Open DOISearch in Google Scholar
Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, et al. Brain tumor eradication and prolonged survival from in-tratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2012; 14: 145-59. doi: 10.1093/neuonc/nor199OstertagDAmundsonKKLopezEspinoza FMartinBBuckleyTGalvãoda Silva APet alBrain tumor eradication and prolonged survival from in-tratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vectorNeuro Oncol2012141455910.1093/neuonc/nor199326638422070930Open DOISearch in Google Scholar
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, et al. Effect of vocimagene amiretrorepvec in combination with Flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol 2020; 6: 1939-46. doi: 10.1001/jamaoncol.2020.3161CloughesyTFPetreccaKWalbertTButowskiNSalaczMPerryJet alEffect of vocimagene amiretrorepvec in combination with Flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trialJAMA Oncol2020619394610.1001/jamaoncol.2020.3161759668533119048Open DOISearch in Google Scholar
Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther 2021; 28: 513-27. doi: 10.1038/s41434-021-00246-wAlbingerNHartmannJUllrichECurrent status and perspective of CAR-T and CAR-NK cell therapy trials in GermanyGene Ther2021285132710.1038/s41434-021-00246-w845532233753909Open DOISearch in Google Scholar
Pikor LA, Bell JC, Diallo JS. Oncolytic viruses: Exploiting cancer’s deal with the devil. Trends in Cancer 2015; 1: 266-77. doi: 10.1016/j.trecan.2015.10.004PikorLABellJCDialloJSOncolytic viruses: Exploiting cancer’s deal with the devilTrends in Cancer201512667710.1016/j.trecan.2015.10.00428741515Open DOISearch in Google Scholar
Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 2018; 18: 419-32. doi: 10.1038/s41568-018-0009-4Twumasi-BoatengKPettigrewJLKwokYYEBellJCNelsonBHOncolytic viruses as engineering platforms for combination immunotherapyNat Rev Cancer2018184193210.1038/s41568-018-0009-429695749Open DOISearch in Google Scholar
Russell SJ, Peng KW. Oncolytic virotherapy: a contest between apples and oranges. Mol Ther 2017; 25: 1107-16. doi: 10.1016/j.ymthe.2017.03.026RussellSJPengKWOncolytic virotherapy: a contest between apples and orangesMol Ther20172511071610.1016/j.ymthe.2017.03.026541784528392162Open DOISearch in Google Scholar
Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 2019; 18: 689-706. doi: 10.1038/s41573-019-0029-0HarringtonKFreemanDJKellyBHarperJSoriaJCOptimizing oncolytic virotherapy in cancer treatmentNat Rev Drug Discov20191868970610.1038/s41573-019-0029-031292532Open DOISearch in Google Scholar
Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol 2017; 3: 841-9. doi: 10.1001/jamaon-col.2016.2064LawlerSESperanzaMCChoCFChioccaEAOncolytic viruses in cancer treatment: a reviewJAMA Oncol20173841910.1001/jamaon-col.2016.2064Open DOISearch in Google Scholar
Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14: 559-67. doi: 10.1038/nrc3770LichtyBDBreitbachCJStojdlDFBellJCGoing viral with cancer immunotherapyNat Rev Cancer2014145596710.1038/nrc377024990523Open DOISearch in Google Scholar
Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, et al. Personalized cancer vaccine platform for clinically relevant oncolytic enveloped viruses. Mol Ther 2018; 26: 2315-25. doi: 10.1016/j. ymthe.2018.06.008YlösmäkiEMalorzoCCapassoCHonkasaloOFuscielloMMartinsBet alPersonalized cancer vaccine platform for clinically relevant oncolytic enveloped virusesMol Ther20182623152510.1016/j.ymthe.2018.06.008612750030005865Open DOISearch in Google Scholar
Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, et al. Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Mol Ther 2021; 29: 555-70. doi: 10.1016/j.ymthe.2020.09.038ShemeshCSHsuJCHosseiniIShenBQRotteATwomeyPet alPersonalized cancer vaccines: Clinical landscape, challenges, and opportunitiesMol Ther2021295557010.1016/j.ymthe.2020.09.038785428233038322Open DOISearch in Google Scholar
Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11. doi: 10.1038/sj.bjc.6600006RiesSKornWMONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirusBr J Cancer20028651110.1038/sj.bjc.6600006274652811857003Open DOISearch in Google Scholar
Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets 2018; 18: 171-6. doi: 10.2174/1568009 618666171129221503LiangMOncorine, the world first oncolytic virus medicine and its update in ChinaCurr Cancer Drug Targets201818171610.2174/156800961866617112922150329189159Open DOISearch in Google Scholar
Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: barriers and recent advances. Mol Ther - Oncolytics 2019; 15: 234-47. doi: 10.1016/j.omto.2019.10.007ZhengMHuangJTongAYangHOncolytic viruses for cancer therapy: barriers and recent advancesMol Ther - Oncolytics2019152344710.1016/j.omto.2019.10.007691194331872046Open DOISearch in Google Scholar
Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006; 13: 975-92. doi: 10.1038/sj.cgt.7700946ShenYNemunaitisJHerpes simplex virus 1 (HSV-1) for cancer treatmentCancer Gene Ther2006139759210.1038/sj.cgt.770094616604059Open DOISearch in Google Scholar
Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780-8. doi: 10.1200/JCO.2014.58.3377AndtbackaRHIKaufmanHLCollichioFAmatrudaTSenzerNChesneyJet alTalimogene laherparepvec improves durable response rate in patients with advanced melanomaJ Clin Oncol2015332780810.1200/JCO.2014.58.337726014293Open DOISearch in Google Scholar
Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, et al Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell 2021; 39: 394-406.e4. doi: 10.1016/j.ccell.2020.12.022RamelyteETastanovaABalázsZIgnatovaDTurkoPMenzelUet alOncolytic virotherapy-mediated anti-tumor response: a single-cell perspectiveCancer Cell202139394406e410.1016/j.ccell.2020.12.02233482123Open DOISearch in Google Scholar
Kaufman HL, Maciorowski D. Advancing oncolytic virus therapy by understanding the biology. Nat Rev Clin Oncol 2021; 18: 197-8. doi: 10.1038/s41571-021-00490-4KaufmanHLMaciorowskiDAdvancing oncolytic virus therapy by understanding the biologyNat Rev Clin Oncol202118197810.1038/s41571-021-00490-433686265Open DOISearch in Google Scholar
Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol 2020; 83: 189-96. doi: 10.1016/j. jaad.2020.01.039HaitzKKhosraviHLinJYMengeTNambudiriVEReview of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanomaJ Am Acad Dermatol2020831899610.1016/j.jaad.2020.01.03932004650Open DOISearch in Google Scholar
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170: 1109-1119.e10. doi: 10.1016/j.cell.2017.08.027RibasADummerRPuzanovIVanderWaldeAAndtbackaRHIMichielinOet alOncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapyCell201717011091119e1010.1016/j.cell.2017.08.027803439228886381Open DOISearch in Google Scholar
Jahan N, Ghouse SM, Martuza RL, Rabkin SD. In situ cancer vaccination and immunovirotherapy using oncolytic HSV. Viruses 2021; 13: 1-27. doi: 10.3390/v13091740JahanNGhouseSMMartuzaRLRabkinSDIn situ cancer vaccination and immunovirotherapy using oncolytic HSVViruses20211312710.3390/v13091740847304534578321Open DOISearch in Google Scholar
Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001; 98: 6396-401. doi: 10.1073/pnas.101136398TodoTMartuzaRLRabkinSDJohnsonPAOncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killingProc Natl Acad Sci U S A200198639640110.1073/pnas.1011363983347911353831Open DOISearch in Google Scholar
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20: 749-58. doi: 10.1038/mt.2011.276ParatoKABreitbachCJLe BoeufFWangJStorbeckCIlkowCet alThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther2012207495810.1038/mt.2011.276332159422186794Open DOISearch in Google Scholar
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics. J Immunother Cancer 2019; 7: 1-21. doi: 10.1186/s40425-018-0495-7GuoZSLuBGuoZGiehlEFeistMDaiEet alVaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolyticsJ Immunother Cancer2019712110.1186/s40425-018-0495-7632581930626434Open DOISearch in Google Scholar
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-36. doi: 10.1038/nm.3089HeoJReidTRuoLBreitbachCJRoseSBloomstonMet alRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med2013193293610.1038/nm.3089426854323396206Open DOISearch in Google Scholar
Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of HCC. Cancers 2021; 13: 1962. doi: 10.3390/cancers13081962FoersterFGallePRThe current landscape of clinical trials for systemic treatment of HCCCancers202113196210.3390/cancers13081962807347133921731Open DOISearch in Google Scholar
Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nat Rev Urol 2021; 18: 170-84. doi: 10.1038/s41585-021-00431-xGreggJRThompsonTCConsidering the potential for gene-based therapy in prostate cancerNat Rev Urol2021181708410.1038/s41585-021-00431-x33637962Open DOISearch in Google Scholar
Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III Trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol 2019; 37: 1051-61. doi: 10.1200/JCO.18.02031GulleyJLBorreMVogelzangNJNgSAgarwalNParkerCCet alPhase III Trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancerJ Clin Oncol20193710516110.1200/JCO.18.02031649436030817251Open DOISearch in Google Scholar
Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18: 1001-11. doi: 10.1517/13543780902997928MadanRAArlenPMMohebtashMHodgeJWGulleyJLProstvac-VF: a vector-based vaccine targeting PSA in prostate cancerExpert Opin Investig Drugs20091810011110.1517/13543780902997928344927619548854Open DOISearch in Google Scholar
Shi T, Song X, Wang Y, Liu F, Wei J. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front Immunol 2020; 11: 1-13. doi: 10.3389/fimmu.2020.00683ShiTSongXWangYLiuFWeiJCombining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatmentFront Immunol20201111310.3389/fimmu.2020.00683719876032411132Open DOISearch in Google Scholar
Moleirinho MG, Silva RJS, Alves PM, Carrondo MJT, Peixoto C. Current challenges in biotherapeutic particles manufacturing. Expert Opin Biol Ther 2019; 20: 451-65. doi: 10.1080/14712598.2020.1693541MoleirinhoMGSilvaRJSAlvesPMCarrondoMJTPeixotoCCurrent challenges in biotherapeutic particles manufacturingExpert Opin Biol Ther2019204516510.1080/14712598.2020.169354131773998Open DOISearch in Google Scholar
Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther - Methods Clin Dev 2016; 3: 16018. doi: 10.1038/mtm.2016.18UngerechtsGBossowSLeuchsBHolmPSRommelaereJCoffeyMet alMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesMol Ther - Methods Clin Dev201631601810.1038/mtm.2016.18482264727088104Open DOISearch in Google Scholar
Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf 2020; 25: 7-18. doi: 10.1177/1535676019899502GhoshSBrownAMJenkinsCCampbellKViral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challengesAppl Biosaf20202571810.1177/1535676019899502Open DOISearch in Google Scholar
Merten OW, Schweizer M, Chahal P, Kamen AA. Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharm Bioprocess 2014; 2: 183-203. doi: 10.4155/pbp.14.16MertenOWSchweizerMChahalPKamenAAManufacturing of viral vectors for gene therapy: part IUpstream processing. Pharm Bioprocess2014218320310.4155/pbp.14.16Open DOISearch in Google Scholar
van der Loo JCM, Wright JF. Progress and challenges in viral vector manufacturing. Hum Mol Genet 2016; 25: R42-52. doi: 10.1093/hmg/ddv451vander Loo JCMWrightJFProgress and challenges in viral vector manufacturingHum Mol Genet201625R425210.1093/hmg/ddv451480237226519140Open DOISearch in Google Scholar
Ferreira MV, Cabral ET, Coroadinha AS. Progress and perspectives in the development of lentiviral vector producer cells. Biotechnol J 2021; 16. doi: 10.1002/biot.202000017FerreiraMVCabralETCoroadinhaASProgress and perspectives in the development of lentiviral vector producer cellsBiotechnol J20211610.1002/biot.20200001732686901Open DOISearch in Google Scholar
Tomás HA, Rodrigues AF, Carrondo MJT, Coroadinha AS. LentiPro26: novel stable cell lines for constitutive lentiviral vector production. Sci Rep 2018; 8: 1-11. doi: 10.1038/s41598-018-23593-yTomásHARodriguesAFCarrondoMJTCoroadinhaASLentiPro26: novel stable cell lines for constitutive lentiviral vector productionSci Rep2018811110.1038/s41598-018-23593-y586959829588490Open DOISearch in Google Scholar
Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 2015; 10: 702-14. doi: 10.1002/biot.201400438FelberbaumRSThe baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectorsBiotechnol J2015107021410.1002/biot.201400438715933525800821Open DOISearch in Google Scholar
Kurasawa JH, Park A, Sowers CR, Halpin RA, Tovchigrechko A, Dobson CL, et al Chemically defined, high-density insect cell-based expression system for scalable AAV vector production. Mol Ther Methods Clin Dev 2020; 19: 330-40. doi: 10.1016/j.omtm.2020.09.018KurasawaJHParkASowersCRHalpinRATovchigrechkoADobsonCLet alChemically defined, high-density insect cell-based expression system for scalable AAV vector productionMol Ther Methods Clin Dev2020193304010.1016/j.omtm.2020.09.018759133133145369Open DOISearch in Google Scholar
Gupta P, Monge M, Boulais A, Chopra N, Hutchinson N. Single-use process platforms for responsive and cost-effective manufacturing. In: Eibl R, Eibl D, editors. Single-use technology in biopharmaceutical manufacture. Hoboken, NY, USA: John Wiley & Sons, Inc 2019. p. 201-10. doi: 10.1002/9781119477891.ch16GuptaPMongeMBoulaisAChopraNHutchinsonNSingle-use process platforms for responsive and cost-effective manufacturing. In: Eibl R, Eibl D, editors. Single-use technology in biopharmaceutical manufactureHoboken, NY, USAJohn Wiley & Sons, Inc2019p2011010.1002/9781119477891.ch16Open DOISearch in Google Scholar
Minh A, Kamen AA. Critical assessment of purification and analytical technologies for enveloped viral vector and vaccine processing and their current limitations in resolving co-expressed extracellular vesicles. Vaccines 2021; 9: 823. doi: 10.3390/vaccines9080823MinhAKamenAACritical assessment of purification and analytical technologies for enveloped viral vector and vaccine processing and their current limitations in resolving co-expressed extracellular vesiclesVaccines2021982310.3390/vaccines9080823840240734451948Open DOISearch in Google Scholar
Merten O-W, Schweizer M, Chahal P, Kamen A. Manufacturing of viral vectors: part II. Downstream processing and safety aspects. Pharm Bioprocess 2014; 2: 237-51. http://www.future-science.com/doi/abs/10.4155/pbp.14.15%0Apapers2://publication/doi/10.4155/pbp.14.15MertenO-WSchweizerMChahalPKamenAManufacturing of viral vectors: part IIDownstream processing and safety aspects. Pharm Bioprocess2014223751http://www.future-science.com/doi/abs/10.4155/pbp.14.15%0Apapers2://publication/doi/10.4155/pbp.14.1510.4155/pbp.14.15Search in Google Scholar
Kaemmerer WF. How will the field of gene therapy survive its success? Bioeng Transl Med 2018; 3: 166-77. doi: 10.1002/btm2.10090KaemmererWFHow will the field of gene therapy survive its success?Bioeng Transl Med201831667710.1002/btm2.10090606387030065971Open DOISearch in Google Scholar
Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther 2018; 26: 2717-26. doi: 10.1016/j. ymthe.2018.10.017SalzmanRCookFHuntTMalechHLReillyPFoss-CampbellBet alAddressing the value of gene therapy and enhancing patient access to transformative treatmentsMol Ther20182627172610.1016/j.ymthe.2018.10.017627750930414722Open DOISearch in Google Scholar
Capra E, Godfrey A, Loche A, Smith J. Innovation in viral-vector gene therapy: unlocking the promise. [cited 2021 Dec 24]. Available at https://www.mckinsey.com/industries/life-sciences/our-insights/gene-therapy-innovation-unlocking-the-promise-of-viral-vectorsCapraEGodfreyALocheASmithJInnovation in viral-vector gene therapy: unlocking the promise. [cited 2021 Dec 24]Available athttps://www.mckinsey.com/industries/life-sciences/our-insights/gene-therapy-innovation-unlocking-the-promise-of-viral-vectorsSearch in Google Scholar
Wolf MW, Reichl U. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 2011; 10: 1451-75. doi: 10.1586/erv.11.111WolfMWReichlUDownstream processing of cell culture-derived virus particlesExpert Rev Vaccines20111014517510.1586/erv.11.111710368121988309Open DOISearch in Google Scholar
Martin NT, Bell JC. Oncolytic virus combination therapy: killing one bird with two stones. Mol Ther 2018; 26: 1414-22. doi: 10.1016/j. ymthe.2018.04.001MartinNTBellJCOncolytic virus combination therapy: killing one bird with two stonesMol Ther20182614142210.1016/j.ymthe.2018.04.001598672629703699Open DOISearch in Google Scholar
Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K, Koshy S, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009; 17: 1814-21. doi: 10.1038/mt.2009.154BridleBWBoudreauJELichtyBDBrunellièreJStephensonKKoshySet alVesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirusMol Ther20091718142110.1038/mt.2009.154283501019603003Open DOISearch in Google Scholar
